Abstract: The present invention relates to a pharmaceutical composition for the inhibition of cancer metastasis, more precisely, a novel pharmaceutical composition against cancer metastasis comprising lipocalin 2 protein, a gene encoding the protein, an expression vector containing the gene or cells transfected with the expression vector as an effective ingredient, a method for the inhibition of cancer metastasis using the composition, a diagnostic kit for the prediction of cancer metastasis, a method for the selection of a metastasis risk group using the kit, a novel pharmaceutical composition for the inhibition of cancer growth and a method for the inhibition of cancer growth using the same. The pharmaceutical composition of the present invention specifically inhibits cancer metastasis, so that it can improve the effect of cancer treatment dramatically.

Abstract: An organic electroluminescent display (OELD) device comprises a first electrode on a first substrate having an active region and a non-active region at periphery of the active region, the active region including a plurality of pixel regions and the non-active region including a power supply region; an organic luminescent layer on the first electrode in the plurality of pixel regions; a first organic layer on the first electrode in the power supply region; a second organic layer on the first substrate in an outer region of the power supply region; a second electrode on the organic luminescent layer; a driving thin film transistor connected to the second electrode and formed on a second substrate; and a power supply terminal connected to the first organic layer and formed on the second substrate, wherein the first organic layer has substantially the same shape as the organic luminescent layer, and the second organic layer has substantially a different shape from the organic luminescent layer.

Abstract: The present invention relates to a method for reducing the fucose content of a recombinant protein, which comprises expressing in an animal cell the recombinant protein and FUCA1, an FUCA1 mutant, FUCA2, or a fragment of FUT8 localization domain; or with a fusion protein of a fragment of FUT8 localization domain and a fragment of FUCA1, a FUCA1 mutant or FUCA2. Therefore, the antibody expressed according to the method of the present invention exhibits a reduced fucose content in their Fc regions, which leads to the improvement in the therapeutic effect thereof.

Abstract: The present invention relates to a pharmaceutical composition for the inhibition of cancer metastasis, more precisely, a novel pharmaceutical composition against cancer metastasis comprising lipocalin 2 protein, a gene encoding the protein, an expression vector containing the gene or cells transfected with the expression vector as an effective ingredient, a method for the inhibition of cancer metastasis using the composition, a diagnostic kit for the prediction of cancer metastasis, a method for the selection of a metastasis risk group using the kit, a novel pharmaceutical composition for the inhibition of cancer growth and a method for the inhibition of cancer growth using the same. The pharmaceutical composition of the present invention specifically inhibits cancer metastasis, so that it can improve the effect of cancer treatment dramatically.

Abstract: An organic electroluminescent display (OELD) device comprises a first electrode on a first substrate having an active region and a non-active region at periphery of the active region, the active region including a plurality of pixel regions and the non-active region including a power supply region; an organic luminescent layer on the first electrode in the plurality of pixel regions; a first organic layer on the first electrode in the power supply region; a second organic layer on the first substrate in an outer region of the power supply region; a second electrode on the organic luminescent layer; a driving thin film transistor connected to the second electrode and formed on a second substrate; and a power supply terminal connected to the first organic layer and formed on the second substrate, wherein the first organic layer has substantially the same shape as the organic luminescent layer, and the second organic layer has substantially a different shape from the organic luminescent layer.

Abstract: The present invention relates to a variant of Lkn-1(shLkn-1) with enhanced biological activity, which is a truncated form of Lkn-1, a process for preparing a recombinant shLkn-1 by employing expression vector therefor and pharmaceutical application of the said protein. shLkn-1 is generated by missing 26 amino acid residues from the amino terminus of Lkn-1 to contain 66 amino acids. Recombinant shLkn-1 inhibits colony formation and cell proliferation in vivo, which suggests that it can be used as a potential drug for the antibody production, the treatment during HIV-1 infection, the protection of bone marrow stem cells during chemotherapy or radiotherapy, and the inhibition of leukemia.